Abstract
BACKGROUND: The Japan-Multinational Trial Organization (JMTO) lung cancer (LC) 0003 was a prospective randomized phase III trial investigating advanced non-small cell lung cancer comparing paclitaxel (P) plus carboplatin (C) versus vinorelbine (V), gemcitabine (G) followed by docetaxel (D). This trial was conducted with Southwest Oncology Group (SWOG) 0003 using a common arm of PC. An analysis of SWOG 0003 samples showed that low osteopontin (OPN) plasma levels were highly prognostic for a better outcome. We performed an independent investigation to validate these results using samples from Japanese patients enrolled in the JMTO LC 0004, a correlative study associated with JMTO LC 0003. METHODS: A total of 20 ml of blood was collected before treatment from patients enrolled in JMTO LC 0003. Serum concentrations of OPN and basic fibroblast growth factor (bFGF) were measured by enzyme-linked immunosorbent assay. Effects of OPN and bFGF levels on tumor response, progression-free survival (PFS), and overall survival (OS) were examined. RESULTS: Seventy-one samples were obtained, including 32 specimens from the PC arm and 39 from the VGD arm. There were no significant relationships between either OPN or bFGF levels with patient characteristics. In an analysis of clinical outcome, low OPN levels correlated with better OS and progression-free survival (hazard ratio [HR] = 0.57; 95% confidence interval [CI], 0.33-0.97; p = 0.037, HR = 0.42; 95% CI, 0.25-0.70; p = 0.001, respectively) and high bFGF levels correlated with better OS (HR = 0.53; 95% CI, 0.31-0.90; p = 0.018). CONCLUSION: Consistent with the findings from SWOG 0003, low OPN serum levels were significantly associated with a favorable prognosis in the JMTO LC 0004. Additionally, high bFGF levels were associated with improved survival.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1104-1110 |
| Number of pages | 7 |
| Journal | Journal of Thoracic Oncology |
| Volume | 4 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2009 |
Fingerprint
Keywords
- BFGF
- Correlative study
- Non-small cell lung cancer
- Osteopontin
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer : Results from JMTO LC 0004. / Isa, Shun Ichi; Kawaguchi, Tomoya; Teramukai, Satoshi; Minato, Koichi; Ohsaki, Yoshinobu; Shibata, Kazuhiko; Yonei, Toshirou; Hayashibara, Kenji; Fukushima, Masanori; Kawahara, Masaaki; Furuse, Kiyoyuki; Mack, Philip.
In: Journal of Thoracic Oncology, Vol. 4, No. 9, 09.2009, p. 1104-1110.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer
T2 - Results from JMTO LC 0004
AU - Isa, Shun Ichi
AU - Kawaguchi, Tomoya
AU - Teramukai, Satoshi
AU - Minato, Koichi
AU - Ohsaki, Yoshinobu
AU - Shibata, Kazuhiko
AU - Yonei, Toshirou
AU - Hayashibara, Kenji
AU - Fukushima, Masanori
AU - Kawahara, Masaaki
AU - Furuse, Kiyoyuki
AU - Mack, Philip
PY - 2009/9
Y1 - 2009/9
N2 - BACKGROUND: The Japan-Multinational Trial Organization (JMTO) lung cancer (LC) 0003 was a prospective randomized phase III trial investigating advanced non-small cell lung cancer comparing paclitaxel (P) plus carboplatin (C) versus vinorelbine (V), gemcitabine (G) followed by docetaxel (D). This trial was conducted with Southwest Oncology Group (SWOG) 0003 using a common arm of PC. An analysis of SWOG 0003 samples showed that low osteopontin (OPN) plasma levels were highly prognostic for a better outcome. We performed an independent investigation to validate these results using samples from Japanese patients enrolled in the JMTO LC 0004, a correlative study associated with JMTO LC 0003. METHODS: A total of 20 ml of blood was collected before treatment from patients enrolled in JMTO LC 0003. Serum concentrations of OPN and basic fibroblast growth factor (bFGF) were measured by enzyme-linked immunosorbent assay. Effects of OPN and bFGF levels on tumor response, progression-free survival (PFS), and overall survival (OS) were examined. RESULTS: Seventy-one samples were obtained, including 32 specimens from the PC arm and 39 from the VGD arm. There were no significant relationships between either OPN or bFGF levels with patient characteristics. In an analysis of clinical outcome, low OPN levels correlated with better OS and progression-free survival (hazard ratio [HR] = 0.57; 95% confidence interval [CI], 0.33-0.97; p = 0.037, HR = 0.42; 95% CI, 0.25-0.70; p = 0.001, respectively) and high bFGF levels correlated with better OS (HR = 0.53; 95% CI, 0.31-0.90; p = 0.018). CONCLUSION: Consistent with the findings from SWOG 0003, low OPN serum levels were significantly associated with a favorable prognosis in the JMTO LC 0004. Additionally, high bFGF levels were associated with improved survival.
AB - BACKGROUND: The Japan-Multinational Trial Organization (JMTO) lung cancer (LC) 0003 was a prospective randomized phase III trial investigating advanced non-small cell lung cancer comparing paclitaxel (P) plus carboplatin (C) versus vinorelbine (V), gemcitabine (G) followed by docetaxel (D). This trial was conducted with Southwest Oncology Group (SWOG) 0003 using a common arm of PC. An analysis of SWOG 0003 samples showed that low osteopontin (OPN) plasma levels were highly prognostic for a better outcome. We performed an independent investigation to validate these results using samples from Japanese patients enrolled in the JMTO LC 0004, a correlative study associated with JMTO LC 0003. METHODS: A total of 20 ml of blood was collected before treatment from patients enrolled in JMTO LC 0003. Serum concentrations of OPN and basic fibroblast growth factor (bFGF) were measured by enzyme-linked immunosorbent assay. Effects of OPN and bFGF levels on tumor response, progression-free survival (PFS), and overall survival (OS) were examined. RESULTS: Seventy-one samples were obtained, including 32 specimens from the PC arm and 39 from the VGD arm. There were no significant relationships between either OPN or bFGF levels with patient characteristics. In an analysis of clinical outcome, low OPN levels correlated with better OS and progression-free survival (hazard ratio [HR] = 0.57; 95% confidence interval [CI], 0.33-0.97; p = 0.037, HR = 0.42; 95% CI, 0.25-0.70; p = 0.001, respectively) and high bFGF levels correlated with better OS (HR = 0.53; 95% CI, 0.31-0.90; p = 0.018). CONCLUSION: Consistent with the findings from SWOG 0003, low OPN serum levels were significantly associated with a favorable prognosis in the JMTO LC 0004. Additionally, high bFGF levels were associated with improved survival.
KW - BFGF
KW - Correlative study
KW - Non-small cell lung cancer
KW - Osteopontin
UR - http://www.scopus.com/inward/record.url?scp=69549097610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69549097610&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e3181ae2844
DO - 10.1097/JTO.0b013e3181ae2844
M3 - Article
VL - 4
SP - 1104
EP - 1110
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 9
ER -